Generated by AI
Bicycle Therapeutics plc - ADR is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycle molecules. The company applies its proprietary bicyclic peptide platform to create targeted therapies designed to address diseases that are underserved by existing treatments, with a primary emphasis on oncology and other serious conditions. Its current pipeline includes Bicycle toxin conjugates and related precision medicine programs that are being evaluated in clinical trials for tumor types and other disease areas. Bicycle Therapeutics also works with partners to extend its technology into additional therapeutic applications, including radiopharmaceutical and non-oncology research. Based in Cambridge, United Kingdom, Bicycle Therapeutics plc - ADR plays a specialized role in the biotechnology market by advancing highly selective drug candidates that combine small-molecule-like properties with peptide-based targeting.
WebsitePortway Building
Cambridge, CB21 6GS
United Kingdom
The latest articles about BCYC.
Detailed price information for Bicycle Therapeutics Plc ADR (BCYC-Q) from The Globe and Mail including charting and trades.
Summary of Oct 5's posts. Generated by AI.
No summary yet.
Summary of Oct 8's posts. Generated by AI.
Summary of Apr 11's posts. Generated by AI.
Investors talking about BCYC also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.